Assessment of miR-223 expression on placenta in gestational diabetes

Objective: The placenta is regulator of materno-fetal transport of nutrients and gases. Alterations in placental transport functions can modify the impact of metabolic abnormalities of GDM on the developing fetus. Severe adiponectin deficiency in the third trimester of pregnancy has been associated with risks of placenta-mediated complications of GDM. Placental expressions of characterized miRNAs is thought to play an important role in the diagnosis of GDM as novel and effective biomarkers. We aimed to estimated the association between third-trimester miR-223 expressions of placenta and adiponectin levels of serum. Method: This study included placental tissue and serum was obtained from third trimester pregnancies. Maternal serum concentrations of adiponectin and placental sample expressions of miR-223 were measured. Expressions of miR-223 in the placenta were evaluated Real-time PCR and levels of adiponectin was determined by ELISA method. Results: According to the findings of Real-time PCR, expression of miR-223 decreased in the statistically significant range in GDM group compared to control group in placenta. According to the findings of ELISA, expression of adiponectin decreased in GDM group compared to control group in serum, but there was not statistically significant difference between other groups. Conclusion: To conclude, miR-223 is considered to be a novel biomarker related to diagnosis and treatment of GDM. Given the abundant, recent literature, it is now increasingly clear that adiponectin also known as in the regulation of maternal, fetal and placental process may potentially contribute to better expression of miR-223 on placenta, with further evidence needed to clarify its true in this with GDM. Key words: Gestationel diabetes mellitus, placenta, microRNA-223, adiponectin